Dykema Advises PowerUp Acquisition Corp. in its Combination with Visiox Pharmaceuticals, Inc.

Dykema advised PowerUp Acquisition Corp in a business combination with Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq. Visiox’s pipeline of an FDA Approved drug candidate, and other late-stage clinical drug candidates, includes treatments for patients with ocular hypertension, open angle glaucoma, and post-surgical inflammation and pain. Visiox’s mission is to develop and commercialize ophthalmic treatments in large markets with high unmet needs. Visiox’s pipeline of both New Chemical Entity (NCE) and 505(b)(2) products address highly prevalent disease states in need of new treatment options. Globally, glaucoma affects more than 80 million people, and there are more than 6 million ocular surgeries in the United States every year.

The Dykema team that worked on the transaction included Kate Bechen, Andrew Frost, Taylor Browne, and Jill Knutson.

To read more, check out the transaction’s official press release.